Contents
Phenobarbital therapy has been shown to be effective in reducing plasma bilirubin levels in patients with Crigler-Najjar syndrome type 2. Administration of 60-180 mg/day of the drug (in divided doses) can reduce serum bilirubin levels by at least 25%. A response should be expected within 2-3 weeks.
Disclaimer:
The content is intended to augment, not replace, information provided by your clinician. It is not intended nor implied to be a substitute for professional medical advice. Reading this information does not create or replace a doctor-patient relationship or consultation. If required, please contact your doctor or other health care provider to assist you to interpret any of this information, or in applying the information to your individual needs.